0001192482-19-000222.txt : 20190429
0001192482-19-000222.hdr.sgml : 20190429
20190429185543
ACCESSION NUMBER: 0001192482-19-000222
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190425
FILED AS OF DATE: 20190429
DATE AS OF CHANGE: 20190429
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fallon John A.
CENTRAL INDEX KEY: 0001560152
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37372
FILM NUMBER: 19777755
MAIL ADDRESS:
STREET 1: C/O INSULET CORPORATION
STREET 2: 9 OAK PARK DRIVE
CITY: BEDFORD
STATE: MA
ZIP: 01730
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC
CENTRAL INDEX KEY: 0001267565
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: VA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 TECHNOLOGY CENTER DRIVE
CITY: STOUGHTON
STATE: MA
ZIP: 02072
BUSINESS PHONE: 781-713-3699
MAIL ADDRESS:
STREET 1: 100 TECHNOLOGY CENTER DRIVE
CITY: STOUGHTON
STATE: MA
ZIP: 02072
FORMER COMPANY:
FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC
DATE OF NAME CHANGE: 20031020
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2019-04-25
0001267565
COLLEGIUM PHARMACEUTICAL, INC
COLL
0001560152
Fallon John A.
C/O COLLEGIUM PHARMACEUTICAL, INC.
100 TECHNOLOGY CENTER DRIVE
STOUGHTON
MA
02072
1
0
0
0
Common Stock
2019-04-25
4
A
0
4707
0
A
9335
D
Stock Option (Right to Purchase)
14.57
2019-04-25
4
A
0
9414
0
A
2029-04-25
Common Stock
9414
9414
D
Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on April 25, 2020, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock.
The option vests and becomes exercisable on April 25, 2020, subject to the director's continued service with the issuer.
/s/ Paul Brannelly as Attorney-In-Fact For John A. Fallon, M.D.
2019-04-29